To achieve our goals, we analyzed several biomarkers related to AD pathophysiology such as Aβ42, tau protein abnormalities (phosphorylated tau protein, P-tau protein), and indicators of neurodegeneration including total tau protein (T-tau protein) and MRI findings. This evidence concerns the gene MAPT and Alzheimer disease.